The Landscape of Generics and AI in Pharma

This chapter examines the pharmaceutical industry's shift towards generic and biosimilar drugs after patent expirations, highlighting their cost-saving benefits and market innovation. It also discusses the potential impacts of proposed tariffs on drug pricing and domestic manufacturing, alongside the significance of currency fluctuations on profitability. Additionally, the conversation introduces advancements in AI technology and its implications for the pharmaceutical sector, emphasizing the balance of risk and opportunity.